ASBM Chairman Moderates Webinar at DDNC Policy Conference

December 8, 2021

On November 15th, ASBM Chairman Ralph McKibbin, MD moderated a panel discussion at the Digestive Disease National Coalition’s Fall policy-setting forum. The Fall Forum ran from November 15th-19th and gathered together policymakers, caregivers, and patients to discuss the latest developments in digestive disease policy. The webinar included an overview of DDNC funding priorities, presentations from DDNC member […]

Read More


ASBM Letter Opposes BIll That Would Undermine Physician-Patient Relationship

December 8, 2021

House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship On December 2nd, ASBM sent a letter to House leaders reiterating our opposition. The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar. The bill calls for […]

Read More


ASBM’s Madelaine Feldman Testifies at House Oversight Committee

December 2, 2021

On November 17th, ASBM’s Immediate Past Chair Madelaine Feldman, MD, FACR testified at a public hearing of the Congressional Oversight Committee. Entitled “Reviewing the Role of Pharmacy Benefit Managers in Pharmaceutical Markets”, the hearing examined the role of PBMs in contributing to higher drug prices. From Dr. Feldman’s testimony: The out-of-pocket costs for these miraculous RA medications […]

Read More


ASBM Presents at World Biosimilar Congress Europe

November 15, 2021

From November 9th-11th, ASBM participated in the World Biosimilar Congress 2021 Europe, held in Basel, Switzerland. ASBM was represented at the conference by Advisory Board Chair Philip Schneider and Steering Committee Member Andrew Spiegel, executive director of the Global Colon Cancer Association (GCCA). The theme of the three-day meeting was “Celebrating 15 years of Biosimilars […]

Read More


October 2021 Newsletter

November 8, 2021

House Bill Would Distort Treatment Decisions, Undermine Physician-Patient Relationship   The U.S. House of Representatives Committee on Rules has released new language for H.R. 5376 containing a provision that would pay physicians a 33% bonus for prescribing their patient the government-preferred biosimilar.   The bill calls for a “temporary increase in Medicare Part B payments for certain biosimilars,” […]

Read More


ASBM Presents at World Drug Safety Congress USA 2021

November 8, 2021

On October 21st, ASBM’s Philip Schneider participated in the World Drug Safety Congress USA 2021, held in Boston, MA. Dr. Schneider led a panel discussion on improving pharmacovigilance programs globally. Panelists were in general agreement that there is a greater need for improving the quality of adverse drug event reports, particularly in developed countries. Improvement of […]

Read More


Help Celebrate the First National Biologic Coordinator’s Day

November 1, 2021

Today, November 1st, is the First National Biologic Coordinator’s Day.  Starting and staying on a prescribed biologic treatment can be a complex process for patients—but it doesn’t always have to be. Thanks to the tireless work of BIOLOGIC COORDINATORS, patients are able to access their prescribed biologic treatments. A biologic coordinator is a key member of […]

Read More


ASBM Presents Third Biosimilars Course with LIU-Pharmacy

September 30, 2021

On September 28th, ASBM Advisory Board Chair Philip Schneider presented an online Continuing Education (CE) course entitled the “The State of the Biosimilars Market in 2021”. The course was presented in conjunction with Long Island University College of Pharmacy and is the third in the series “Biosimilars: What Pharmacists Need to Know”. The series is accredited by the […]

Read More


Michael Reilly Op-eds in Ontario, Quebec, New Brunswick: Forced Switching Puts Provinces on Wrong Track

September 30, 2021

During the months of September and October, three op-eds by ASBM Executive Director Michael Reilly ran in numerous Canadian papers throughout Quebec, New Brunswick, and Ontario. Quebec and New Brunswick recently announced they would be adopting forced biosimilar switching policies. Ontario has considered, but not yet implemented such a move. Read the Quebec op-ed here (French) Read the New […]

Read More


GaBI Journal Publishes Critical Review of Canadian Substitution Policies

September 30, 2021

On September 30th, the Generics and Biosimilars Initiative published GaBI Journal, Volume 10, 2021, Issue 3, containing a new whitepaper by ASBM Executive Director Michael Reilly and Advisory Board Chair Philip Schneider. The paper is entitled “A Critical Review of Substitution Policy for Biosimilars in Canada” and highlights the stark contrast between the forced-substitution policies recently enacted by some Canadian provinces and the pro-competition policies […]

Read More